A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

计划入组 110 人 · 首次发布于 2025 年 1 月 15 日

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

计划入组 24 人 · 首次发布于 2021 年 7 月 15 日

A Phase 2 Clinical Study of ABSK061 and ABSK043

计划入组 202 人 · 首次发布于 2024 年 10 月 9 日

FGFR2/3 antagonists(Incyte)

FGFR2/3 TARGET therapy (InSilico Medicine)

FGFR2/3/4 inhibitor(Applied Pharmaceutical Science)

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

HARMONICARE Receives FDA Approval for FGFR2/3 Inhibitor ABSK061 Clinical Trial in Pediatric Achondroplasia

Abbisko Cayman Initiates Phase II Trial of ABSK061 and ABSK043 for Advanced Solid Tumors

Cogent Biosciences Unveils Promising KRAS Inhibitor Data with Superior Efficacy Profile